Keywords: Galapagos, Rheumatoid arthritis, Ph IIa, JAK1 inhibitor, GLPG0634, Tofacitinib, Fostamatinib

Unexpectedly strong data for Galapagos rheumatoid arthritis drug candidate

Article | 24 November 2011

Shares of Belgium-based biotech firm Galapagos (Euronext: GLPG) jumped 22% on Tuesday and a further 12% yesterday to 8.10 euros, after the firm ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Galapagos

Pfizer

AstraZeneca

Go to company listing

Related Drugs

tofacitinib

fostamatinib

Go to drug listing